Dysmenorrhea - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Dysmenorrhea - Pipeline Review, H2 2014', provides an overview of the Dysmenorrhea's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dysmenorrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dysmenorrhea and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Dysmenorrhea - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dysmenorrhea and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dysmenorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dysmenorrhea pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Dysmenorrhea - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Dysmenorrhea pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Dysmenorrhea Overview 6 Therapeutics Development 7 Pipeline Products for Dysmenorrhea - Overview 7 Pipeline Products for Dysmenorrhea - Comparative Analysis 8 Dysmenorrhea - Therapeutics under Development by Companies 9 Dysmenorrhea - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Dysmenorrhea - Products under Development by Companies 12 Dysmenorrhea - Companies Involved in Therapeutics Development 13 Jiangsu Kanion Pharmaceutical Co., Ltd. 13 Merck & Co., Inc. 14 ObsEva SA 15 PDC Biotech GmbH 16 Dysmenorrhea - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 etonogestrel vaginal ring - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 KYG-0395 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 OBE-002 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 PDC-31 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 PDC-41 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Peptidometics - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Dysmenorrhea - Recent Pipeline Updates 33 Dysmenorrhea - Dormant Projects 34 Dysmenorrhea - Discontinued Products 35 Dysmenorrhea - Product Development Milestones 36 Featured News & Press Releases 36 Dec 10, 2012: PDC Biotech Completes Phase I Study Of PDC31 For Treatment Of Preterm Labor 36 Nov 15, 2010: PDC Biotech announces start of Phase l trial - novel peptide for treatment of preterm labour and primary dysmenorrhea 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Number of Products under Development for Dysmenorrhea, H2 2014 7 Number of Products under Development for Dysmenorrhea - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Clinical Stage Development, H2 2014 10 Comparative Analysis by Early Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Dysmenorrhea - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2014 13 Dysmenorrhea - Pipeline by Merck & Co., Inc., H2 2014 14 Dysmenorrhea - Pipeline by ObsEva SA, H2 2014 15 Dysmenorrhea - Pipeline by PDC Biotech GmbH, H2 2014 16 Assessment by Monotherapy Products, H2 2014 17 Number of Products by Stage and Target, H2 2014 19 Number of Products by Stage and Mechanism of Action, H2 2014 21 Number of Products by Stage and Route of Administration, H2 2014 23 Number of Products by Stage and Molecule Type, H2 2014 25 Dysmenorrhea Therapeutics - Recent Pipeline Updates, H2 2014 33 Dysmenorrhea - Dormant Projects, H2 2014 34 Dysmenorrhea - Discontinued Products, H2 2014 35
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.